Zhendong pharmaceutical: peeling off idle assets and focusing on two pipelines of tumor and benefit

[chinapharma.com news] recently, Zhendong pharmaceutical announced that the company plans to dispose of the lost pharmaceutical trade assets, idle assets and pipelines with low efficiency at one time, with an estimated transaction value of about 1 billion yuan After the sale of assets, it is estimated that the annual loss of pharmaceutical trade industry will be reduced by 46.67 million yuan, the annual cost will be reduced by 39 million yuan after the disposal of idle assets, and the annual cost will be reduced by 55.7 million yuan After the completion of this transaction, on the one hand, it can increase the liquidity of the company's own funds, concentrate advantageous resources and release the marketing team On the other hand, Zhendong pharmaceutical will "dress up lightly" and accelerate the focus on two major pipelines of tumor and benefit, and the pipeline utilization rate and the company's profitability will continue to improve In recent years, the separation of idle assets and benefits does not highlight the pipeline The pharmaceutical logistics field with a market value of trillions has become an emerging market where e-commerce logistics giants such as Jingdong and Shunfeng are competing to layout However, in the relatively special field of pharmaceutical logistics, the market still needs to break through the development bottleneck of multi-level, high cost, low degree of informatization, poor coordination of supply chain and so on Due to technical reasons, there are also some problems in pharmaceutical logistics, such as information opacity, state and process information uncontrollable, temperature information uncontrollable, information response weak and so on In view of the objective factors of the pharmaceutical logistics market and the actual operation of the company in recent years, the pharmaceutical trading system including Shanxi Zhendong Pharmaceutical Trading Co., Ltd., Shanxi Zhendong Pharmaceutical Co., Ltd., Shanxi Zhendong Pharmaceutical Logistics Co., Ltd., Datong Zhendong Renhe Pharmaceutical Co., Ltd and Yuncheng branch of Shanxi Zhendong pharmaceutical Logistics Co., Ltd is still in a state of loss As for the reasons for the divestiture of idle assets, Zhendong pharmaceutical said that after the new GMP certification, two new factories of Shanxi Zhendong ante biopharmaceutical and Shanxi Zhendong Taisheng pharmaceutical were relocated, and the original plant land was idle, occupying the company's funds Therefore, it is expected that after the sale of the idle assets of ante bio and Taisheng pharmaceutical, the utilization rate of the assets will be further improved, so that the company will step into a more benign development track The announcement also said that the company plans to sell products such as antbio, Taisheng pharmaceutical and other lines with low efficiency At present, Zhendong pharmaceutical has 65 production lines, 11 dosage forms and 601 product specifications These production lines not only have large investment, but also have scattered products, so it is difficult to form large-scale and intensive production, with high cost and no market competitiveness After focusing on the two core pipelines of tumor and benefit, Zhendong pharmaceutical will strengthen the two core pipelines of tumor and benefit, so as to improve the company's benefit Zhendong pharmaceutical said that the company has a self-supporting team of tumor pipeline after 15 years of intensive cultivation, strong academic promotion ability, rich experience in refined management of prescription drugs, and has established a perfect expert network; in terms of tonic products, through the merger and acquisition of Kangyuan pharmaceutical, the company has established a perfect sales channel of tonic products, and the market share of calcium preparations ranks first With the improvement of pipeline utilization and marketing channels, the company's profitability will continue to improve, and its performance will enter a high-speed growth channel According to the first quarter report disclosed by the company, the company achieved an operating revenue of 773 million yuan, up 7.6% year on year According to the plan, in 2018, Zhendong pharmaceutical will also carry out the two research and development of pemetrexed, fasudil, Yushi Shu gel, and other key products, such as adding regulations, modifying agents and increasing indications It will carry out systematic pharmaceutical, safety and effectiveness studies on Compound Kushen injection, brain Zhen Ning and Qi Zhi Tong Luo, and provide perfect data support This year, ten pieces of Chinese herbal medicines will complete the formulation of national standards, raise the threshold of standards and set up standard barriers Former title: Zhendong pharmaceutical: two pipelines of tumor and benefit